Moreover, EGFR‐mutant NSCLC patients with concurrent RB1 and TP53 alterations have an increased risk of NE transdifferentiation, with 25% presenting with de novo SCLC or eventual small‐cell transformation [65]. Here, EGFR is linked to non-small cell lung carcinoma.